Clinical trial
An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)
NCT06716606 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 12, 2024
- Completion date
- October 23, 2030
- Enrollment
- 514 (estimated)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.